<DOC>
	<DOCNO>NCT00270101</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness epoetin alfa versus placebo reduce transfusion requirement anemic patient multiple myeloma , investigate quality-of-life benefit associate use epoetin alfa . Epoetin alfa genetically engineer protein stimulates red blood cell production .</brief_summary>
	<brief_title>The Effect Epoetin Alfa Anemia Patients With Multiple Myeloma</brief_title>
	<detailed_description>Cancer patient often experience anemia due disease , chemotherapy . Quality life also affect , part fatigue associate anemia . Previous study epoetin alfa suggest achieve high hemoglobin level may improve quality life help patient live longer . This study 12-week randomize , double-blind , placebo-controlled , multicenter study ( open-label extension ) ass effectiveness treatment epoetin alfa reduce need red cell transfusion improve anemia patient multiple myeloma whose hemoglobin le 11 gram per deciliter . There 4 group patient study . Patients first place 2 group accord whether receive least 1 blood transfusion within previous 3 month . Within 2 group , patient randomly assign receive either epoetin alfa placebo 12 week . Dosing initiated 150 unit per kilogram ( U/kg ) inject skin 3 time weekly 4 week , either continue 150 U/kg adjust 300 U/kg accord hemoglobin level remain 8 week . All patient complete 12-week double-blind period eligible continue receive epoetin alfa additional 12 week open-label extension study . The primary measure effectiveness determine number unit blood transfuse , proportion patient require transfusion , number unit transfuse relative whether received transfusion study . Additional effectiveness measure include number patient whose hemoglobin level reach least 12 gram per deciliter ( anemia consider `` correct '' ) increase hemoglobin least 2 gram per deciliter , change percentage red blood cell number develop red blood cell blood . Changes quality-of-life ( Nottingham visual analog scale ) performance score also measure . Safety evaluation ( incidence adverse event , laboratory test , vital sign ) change underlie multiple myeloma assess . The hypothesis study epoetin alfa superior placebo reduce need transfusion improve anemia quality life . Double-blind : Epoetin alfa 150 unit per kilogram ( U/kg ) inject skin 3 time weekly 4 week ; either continue 150 U/kg adjust 300 U/kg accord hemoglobin level remain 8 week . Open-label : dose maintain target hemoglobin range .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients document multiple myeloma define standard criterion , least 6 month elapse since begin chemotherapy selfcare performance score 0 , 1 , 2 , 3 ( patient ' ability perform daily activity , score range 0 [ fully active , disease restriction ] 3 [ capable limited selfcare , confine bed chair 50 % waking hour ] ) life expectancy least 3 month baseline hemoglobin &lt; 11 g/dL baseline count &lt; 100,000 microliter develop red cell ability administer selfinjections Patients clinically significant disease cancer evidence uncontrolled hypertension history seizure untreated iron , folate , Vitamin B12 deficiency receive transfusion within 7 day study entry , androgen therapy within 1 month study entry receive dialysis baseline screening</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>anemia</keyword>
	<keyword>cancer</keyword>
	<keyword>quality life</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>transfusion</keyword>
	<keyword>epoetin alfa</keyword>
	<keyword>epoetin</keyword>
	<keyword>erythropoietin</keyword>
</DOC>